Drug intelligence / Profile preview

live attenuated herpes zoster vaccine (Sinovac Dalian)

Development stage: Preclinical
Lead developer: Sinovac (Dalian) Vaccine Technology
Modality: Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

A live attenuated vaccine being developed by Sinovac (Dalian) Vaccine Technology Co., LTD for the prevention of herpes zoster (shingles). The vaccine utilizes a weakened form of the varicella-zoster virus (VZV) to boost VZV-specific cell-mediated immunity in individuals who have previously been infected with chickenpox. By enhancing the immune system's ability to keep the latent virus in check, the vaccine aims to reduce the incidence and severity of shingles and its complications, such as postherpetic neuralgia. It is currently in the preclinical stage of development.

Other names: herpes zoster (shingles) vaccinelive attenuated VZV vaccine

Beyond the preview

Go deeper on live attenuated herpes zoster vaccine (Sinovac Dalian).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on live attenuated herpes zoster vaccine (Sinovac Dalian).